Drug Trial Radar · NCT04427930
Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial
Last checked: Nov 19, 2026Latest source record: Jul 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
129
Actual
Start
Apr 13, 2020
Primary completion
Dec 23, 2026
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- R-BioIndustry
- Sponsor type
- Industry
- First posted
- Jun 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this follow-up study is to investigate the efficacy and safety of autologous Adipose Tissue derived Mesenchymal stem cells (JOINTSTEM®) in patient with severe Knee Osteoarthritis.
Conditions
- Knee Osteoarthritis
Interventions
JOINTSTEMBiological
Autologous Adipose Tissue derived MSCs
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: 5 Years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Keimyung University Dongsan Medical Center
Daegu, South Korea
KyungHee University Gangdong Hospital
Seoul, South Korea
Gangnam Severance Hospital
Seoul, South Korea
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.